Dashboard PDUFA PDUFA History Dilution Watch Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Track ACOG with free AI briefings, catalyst countdowns, and dilution alerts.

ACOG · Alpha Cognition Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$41.4M Cash on Hand

13.3mo Cash Runway

Follow ACOG by email Get an email when ACOG pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about ACOG, unsubscribe in one click. Privacy

🧪 Trial & FDA Catalysts

Nov 2026 · N/A · Recruiting · Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Glioblastoma
Registry primary completion date, not a results date
Nov 2026 · N/A · Recruiting · Alpha Radiation Emitters Device for the Treatment of Advanced Pancreatic Cancer (Feasibili
Registry primary completion date, not a results date
Dec 2026 · N/A · Recruiting · Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous SCC for Immunocompro
Registry primary completion date, not a results date
Dec 2026 · N/A · Active Trial · Alpha Radiation Emitters Device for the Treatment of Cutaneous, Mucosal or Superficial Sof
Registry primary completion date, not a results date
Dec 2026 · N/A · Recruiting · Alpha Radiation Emitters Device (DaRT) in Combination With Check Point Inhibitor for the T
Registry primary completion date, not a results date
Jan 2027 · N/A · Recruiting · Alpha Radiation Emitters Device (DaRT) for the Treatment of Locally Advanced Pancreatic Ca
Registry primary completion date, not a results date

📊 Drug Pipeline

Drug	Indication	Most advanced trial	Status
Benzgalantamine FDA approved Jul 2024 · Zunveyl	Alzheimer Disease	Phase 4 · NCT07633470	Recruiting
Zorifertinib (AZD3759)	Non-small Cell Lung Cancer	Phase 2/3 · NCT03653546	Completed
Birinapant	High Grade Fallopian Tube Serous Adenocarcinoma	Phase 1/2 · NCT02756130	Withdrawn
[14C]Zorifertinib Oral Formulation	EGFR Mutant Advanced Non-small Cell Lung Cancer	Phase 1 · NCT07620951	Completed
[211At]NaAt	DTC - Differentiated Thyroid Cancer	Phase 1 · NCT07287748	Recruiting

Also used in these trials (approved or third-party drugs, not ACOG's own candidates): Pembrolizumab, Erlotinib Hydrochloride, Gefitinib, Trifluridine And Tipiracil, Carboplatin.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

ACOG holds $41.4M in cash and short-term investments (as of Jun 30, 2026) and burns about $9.3M/quarter from operations, an estimated runway of 13.3 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 57 · Elevated

Cash runway 13 months +18
ATM program on file since Aug 2025 +15
Shelf registration (S-3, Aug 2025) +10
Share count +35% in a year +14

Recent financing filings on SEC EDGAR:

Oct 1, 2025 · Underwritten offering · 424B5
Sep 30, 2025 · Underwritten offering · 424B5
Aug 22, 2025 · Shelf registration with ATM program, up to $75M · S-3
Jul 21, 2025 · Shelf registration · S-3
Jul 1, 2025 · Shelf registration · S-3
Dec 20, 2024 · Private placement (8-K Item 3.02) · 8-K

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ACOG files for a raise →

👥 Who Owns ACOG

Insiders 19.7% Other 5%+ holders 17.8% Institutions (29 holders) 56.1% Public and other holders 6.4%

Holder	Type	Shares	% of shares	As of
Opaleye Management Inc. 10% owner	Insider	3,322,954	15.26%	2026-10-01
AWM Investment Company, Inc.	Institution (13G, 5%+)	2,172,036	9.97%	2025-12-31
James E. Besser	5%+ holder (13G)	1,639,255	7.53%	2026-07-14
MANCHESTER MANAGEMENT COMPANY, LLC	5%+ holder (13G)	1,127,181	5.18%	2025-12-30
Funicular Funds, LP	5%+ holder (13G)	1,114,747	5.12%	2026-02-11
Leonard Powell Mertz Director · +8,437 options	Insider	267,239	1.23%	2026-01-14
Kenneth Anthony Cawkell Director · +8,437 options	Insider	225,717	1.04%	2026-01-14
Michael E. McFadden Chief Executive Officer, Director · +253,796 options	Insider	204,691	0.94%	2026-01-09
Lauren D'Angelo Chief Operating Officer · +106,545 options	Insider	140,695	0.65%	2026-05-19
Phillip Joseph Mertz Director · +8,437 options	Insider	42,263	0.19%	2026-01-14
Robert James Wills Director · +8,437 options	Insider	32,241	0.15%	2026-08-21
Henry Huy Du VP Finance and Accounting · +15,982 options	Insider	20,579	0.09%	2026-01-09

Share count 21,777,868 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full ACOG picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ACOG and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z